Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAH Bridging for Relapsed/Refractory AML
NCT07091006Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07091006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091006.